-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Files Suit Again Amgen (AMGN) Related to Humira Biosimilar
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Reports CHMP Outstanding Issues were Satisfactorily Addressed for CHS-1701 Application
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Receives Scheduling Notice from FDA Related to its CHS-1701 Pegfilgrastim Biosimilar Candidate Granting Type 2 Meeting
-
-
-
-
-
-
-
Coherus Biosciences (CHRS) PT Lowered to $43 at BMO Capital; 'CHS-1701 CRL Disappointing but Issues Addressable - Buy on Weakness'
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Prices 5.15M Shares at $24.25
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Regains All CHS-0214 Development and Commercial Rights from Shire (SHPG)
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Enters $100M Conv. Notes Private Placement
-
51,622 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All